SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD - News), a pioneer in developing medical devices to treat infectious disease, announced today that it has initiated clinical testing the Aethlon Hemopurifier® in human studies being conducted at the Fortis Hospital in Delhi, India. The study, approved by the Ethics Committee for Research at Fortis Hospital, will evaluate safety of the Hemopurifier® in up to ten patients with end-stage renal disease. The Hemopurifier® is a first-in-class medical device to treat infectious disease. The device removes infectious viruses and immunosuppressive proteins from circulation, thus allowing the natural immune response a greater opportunity to overcome viral infection.
